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Abstract
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging risk factor and therapeutic target for cardiovascular
disease. The activity and mass of this enzyme are heritable traits, but major genetic determinants have not been explored in
a systematic, genome-wide fashion. We carried out a genome-wide association study of Lp-PLA2 activity and mass in 6,668
Caucasian subjects from the population-based Framingham Heart Study. Clinical data and genotypes from the Affymetrix
550K SNP array were obtained from the open-access Framingham SHARe project. Each polymorphism that passed quality
control was tested for associations with Lp-PLA2 activity and mass using linear mixed models implemented in the R
statistical package, accounting for familial correlations, and controlling for age, sex, smoking, lipid-lowering-medication use,
and cohort. For Lp-PLA2 activity, polymorphisms at four independent loci reached genome-wide significance, including the
APOE/APOC1 region on chromosome 19 (p=6610
224); CELSR2/PSRC1 on chromosome 1 (p=3610
215); SCARB1 on
chromosome 12 (p=1610
28) and ZNF259/BUD13 in the APOA5/APOA1 gene region on chromosome 11 (p=4610
28). All of
these remained significant after accounting for associations with LDL cholesterol, HDL cholesterol, or triglycerides. For Lp-
PLA2 mass, 12 SNPs achieved genome-wide significance, all clustering in a region on chromosome 6p12.3 near the PLA2G7
gene. Our analyses demonstrate that genetic polymorphisms may contribute to inter-individual variation in Lp-PLA2 activity
and mass.
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Introduction
It is increasingly recognized that inflammation plays an
important role in the development of atherosclerotic cardiovascu-
lar disease. Among the most studied circulating biomarkers of
inflammation in this setting is lipoprotein-associated phospholipase
A2 (Lp-PLA2). Studies in animal models with human-like
lipoprotein metabolism have suggested that Lp-PLA2 activity
contributes to atherosclerosis development, and epidemiological
studies have presented evidence that circulating concentrations of
Lp-PLA2 or elevated activity of the enzyme are associated with
cardiovascular disease after adjusting for established risk factors
[1–3]. This has led to the recent development of an orally active
Lp-PLA2 inhibitor currently in clinical trials for cardiovascular
prevention [3].
Lp-PLA2, also known as platelet-activating factor acetylhydrolase
(PAF-AH), is produced by cells of hematopoietic lineage (mono-
cytes/macrophages, T-lymphocytes, mast cells, megakaryocytes
and platelets). The enzyme reacts with oxidized phospholipids to
generate the pro-inflammatory lipids lysophosphatidylcholine and
oxidized free fatty acids. The relationship between Lp-PLA2 and
atherosclerosis is complex. Lp-PLA2 is non-covalently bound to
human plasma lipoproteins; the binding site on the Lp-PLA2
molecule differs according to whether the carrier lipoprotein is LDL
or HDL [4]. Most Lp-PLA2 is bound to LDL, and subjects with
elevated plasma LDL levels also have high Lp-PLA2 activity [5]. In
epidemiologic studies, Lp-PLA2 activity and mass reflect predom-
inantly LDL-associated Lp-PLA2 [6]. Importantly, Lp-PLA2 is
highly associated with the smallest LDL and HDL subclasses [7]
and with electronegative LDL, which overlaps with small dense
LDL[8].Lp-PLA2boundtoHDLhasamuchlowerspecificactivity
than that bound to LDL[6].Despite the fact that HDL carries some
of the Lp-PLA2 activity in plasma, we and others have found an
inverse relationship between Lp-PLA2 activity and HDL levels [9].
This is likely explained by the fact that small dense LDL (with high
Lp-PLA2 activity) aremoreabundant in subjects withlower levels of
HDL. Small dense LDL are also found in the metabolic syndrome,
which is associated with high Lp-PLA2 activity [10].
Given the importance of Lp-PLA2 as a biomarker of
cardiovascular disease pathogenesis and the development of
therapeutics directed at Lp-PLA2, a better understanding of how
genetic variation controls Lp-PLA2 activity and mass is warranted.
Pursuant to this goal, Schnabel et al. estimated the heritabilities of
Lp-PLA2 activity and mass to be 0.41 and 0.25, respectively, in the
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other cohorts [11,12]. They also conducted a large-scale analysis
of candidate genes, focusing on variants in PLA2G7, the gene that
encodes Lp-PLA2, and other SNPs in inflammatory genes [11].
Their study identified variants of potential interest, but they noted
that no SNPs achieved experiment-wide statistical significance. In
the present study, we conducted a genome-wide association study
(GWAS) to identify additional candidate genes that emerge on a
genome-wide scale. Using genotype and clinical data available on
participants in the Framingham Heart Study, we carried out an
analysis of common genetic variants across the genome to identify
loci associated with Lp-PLA2 activity and mass. For Lp-PLA2
activity, our study revealed four genomic regions reaching
genome-wide significance, all harboring genes involved in lipid
metabolism. For Lp-PLA2 mass, the only associated locus was a
region harboring PLA2G7, the gene that encodes Lp-PLA2.
Results
Table 1 displays clinical characteristics of the population under
study. The Third Generation cohort is younger and has a more
favorable lipid profile as compared to the Offspring cohort. It also
has higher Lp-PLA2 activity, but the variance within each cohort is
similar. Graphical summaries of the genome-wide associations
with Lp-PLA2 activity (Figure 1 and Figure 2) and mass (Figure 3
and Figure 4) are displayed using a quantile-quantile (Q-Q) plot
and a Manhattan plot. The Q-Q plot for each phenotype reveals a
clear departure from the overall-null hypothesis of no associations.
The corresponding Manhattan plots present an alternative view
showing the separation of top hits among the genome-wide
associations. The test statistics that generated these summaries do
not display evidence of inflation (inflation factors=1.007 and
0.998) and hence, we did not adjust for population structure.
Results for all SNPs tested can be found in Table S1 (activity) and
Table S2 (mass).
Loci achieving genome-wide significance for association
with Lp-PLA2 activity
Six SNPs in four distinct loci were associated with Lp-PLA2
activity at a genome-wide level of significance in a model
controlling for age, age
2, sex, cohort, lipid-lowering-medication
use, and smoking (Table 2). The top hit was the SNP ss66185226
(rs41377151), which is identical to the SNP rs4420638. This SNP
Author Summary
Blood levels of lipoprotein-associated phospholipase A2
(Lp-PLA2) show a strong association with atherosclerosis in
humans. This enzyme is made by certain cells of the
immune system, associates with lipoproteins (HDL and
LDL), and is thought to be involved in inflammation.
Studies have shown that Lp-PLA2 is a good predictor of
cardiovascular disease, independent of HDL and LDL
cholesterol levels. This has led to the development of
drugs aimed at inhibiting Lp-PLA2 as a way to treat or
prevent cardiovascular disease. The activity and mass of
Lp-PLA2 are heritable traits, but major genetic determi-
nants have not been explored in a systematic fashion. We
examined genetic variants across the human genome to
identify genes influencing Lp-PLA2 activity and mass. We
studied 6,668 Caucasian subjects from the population-
based Framingham Heart Study. Clinical data and genetic
data on 550,000 genetic variants were available for
association analysis. There was no overlap in the most
significantly associated SNPs for activity and mass. We
identified four distinct gene regions showing highly
significant associations with Lp-PLA2 activity, all of which
are known to include genes involved in cholesterol
metabolism. The only locus associated with Lp-PLA2 mass
was a region harboring PLA2G7, the gene that encodes
lipoprotein-associated phospholipase A2.
Table 1. Descriptive statistics from the Framingham Heart Study population used in the current study.
Offspring
Exam 7
Generation 3
Exam 1 Combined
Sample Size N=3023 N=3645 N=6668
Year of enrollment 1998–2001 2002–2005
Female, N (%) 1609 (53) 1938 (53) 3547 (53)
Smoke Regularly, N (%) 409 (14) 637 (17) 1046 (16)
Diabetes, N (%) 335 (11) 107 (3) 442 (7)
Lipid lowering therapy, N (%) 639 (21) 315 (9) 954 (14)
Mean (SD) Mean (SD) Mean (SD)
Age in years 61 (9) 40 (9) 48 (14)
Lp-PLA2 activity, nmol/ml/min 143(36) 166 (36) 155 (38)
Lp-PLA2 mass, ng/mL 299 (94) 231 (48) 263 (81)
LDL-C, mg/dL 120(33) 112 (32) 116 (32)
HDL-C, mg/dL 54 (17) 54 (16) 54 (17)
Total cholesterol, mg/dL 200 (37) 189 (36) 194 (37)
Triglycerides, mg/dL * 116(88) 92 (75) 103 (81)
Body Mass Index, kg/m
2 28 (5) 27 (6) 27 (5)
Data presented are calculated ignoring familial clustering.
*median and interquartile range.
doi:10.1371/journal.pgen.1000928.t001
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apolipoprotein C-I (APOC1) gene within the APOE/APOC1 gene
cluster on chromosome 19q13.32 (Figure 5). Two other SNPs –
rs599839, located 10 bp downstream of PSRC1 and rs4970834,
located in an intron of CELSR2 – are in moderate linkage
disequilibrium (r
2=0.63) with each other and represent a second
locus that maps to chromosome 1p13.3, which includes the genes
PSRC1, CELSR2, and SORT1. The fourth hit, rs10846744, lies
within an intron of SCARB1 on chromosome 12q24.31. The final
two hits, rs12286037 and rs11820589, are in high linkage
disequilibrium (r
2=0.85), and map to 11q23.3. rs12286037 lies
within an intron of the gene ZNF259, and rs11820589 resides
within the BUD13 gene. Both SNPs are nearby an apolipoprotein
gene cluster containing APOA5, APOA4, APOC3 and APOA1. All
tested SNPs and their p-values can be found in Table S1.
Figure 1. Q-Q plot of genome-wide P values for association with Lp-PLA2 activity. Regression analysis of Lp-PLA2 activity in Caucasians
from the Framingham Heart Study. Model controlled for age, age
2, sex, lipid-lowering medication use, cohort, and smoking status.
doi:10.1371/journal.pgen.1000928.g001
Figure 2. Manhattan plot of genome-wide P values for
association with Lp-PLA2 activity. Polymorphisms in four regions
reached genome-wide significance and are labeled with candidate
genes in the associated region.
doi:10.1371/journal.pgen.1000928.g002
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explained by the top hits, the mixed model presents some
challenges. A measure equivalent to R
2 does not exist because
phenotypic variation is partitioned into two variance components:
an additive polygenic component and residual error. To estimate
the impact that the top activity loci had on explaining the variance
of this trait, we compared models with and without our top SNPs
and found that adding the associated SNPs decreased the
polygenic variance by 4.7% and the residual variance by 3.1%.
Loci achieving genome-wide significance for association
with Lp-PLA2 mass
Twelve SNPs clustered in a region of chromosome 6p12.3
were associated with Lp-PLA2 mass at a genome-wide level of
significance(Figure6).Thetop hit,rs1805017,isa non-synonymous
Figure 3. Q-Q plot of genome-wide P values for association with Lp-PLA2 mass. Regression analysis of Lp-PLA2 activity in Caucasians from
the Framingham Heart Study. Model controlled for age, age
2, sex, lipid lowering medication use, cohort, and smoking status.
doi:10.1371/journal.pgen.1000928.g003
Figure 4. Manhattan plot of genome-wide P values for
association with Lp-PLA2 mass. Only the region around the PLA2G7
gene reached genome-wide significance.
doi:10.1371/journal.pgen.1000928.g004
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associated phospholipase A2. The T allele (corresponding to the
amino acid histidine) was associated with higher Lp-PLA2 mass. A
closer evaluation of this region suggests that linkage disequilibrium
with the top SNP, rs1805017, is driving the remaining associations
in this region.
Analyses of Lp-PLA2 activity, conditioning on mass, and
vice versa
We observed that the top hits for Lp-PLA2 activity and mass did
not overlap. The correlation between activity and mass in the
sample (ignoring familial clustering) was 0.27, so these phenotypes
are not expected to carry the same information. However, the top
mass SNP, rs1805017, was weakly associated with Lp-PLA2
activity (p=1.5610
23), so we investigated whether the activity
association could be explained by this SNP’s association with Lp-
PLA2 mass by including mass as a covariate. Instead, including
Lp-PLA2 mass in the model considerably strengthened the
association of this SNP with activity (Table 3, p=2.1610
212).
Because we observed this notable shift in p-values, we repeated
our genome-wide association analyses, modeling SNP associations
with Lp-PLA2 activity while controlling for Lp-PLA2 mass, and
vice versa (Table 3). For Lp-PLA2 mass, the top hits in the PLA2G7
gene region remained the same, but all p-values became more
significant. In addition, two other SNPs in this region, rs1421378
(p=1610
211) and rs6458511 (p=8610
29), became significant.
We also noted that SNPs near the APOB gene at 2p24.1 now
approached genome-wide significance (p,4610
27) for their
association with mass.
For analysis of Lp-PLA2 activity, controlling for mass uncovered
significant associations with two SNPs in linkage disequilibrium
with each other (r
2=0.70) at the PLA2G7 locus: rs1805017(esti-
mated effect: 24.2, p=1610
212) and rs6901132 (p=5610
29).
The T allele of rs1805017 (histidine), associated with increased
mass in our analysis, was associated with decreased activity.
Controlling for mass also strengthened the association at the
APOE/APOC1 locus (p=1.5610
228) and weakened the associa-
tion at the SCARB1 locus (p=1.5610
25). We quantified the
amount of variance in activity explained by the rs1805017 SNP
along with the SNPs previously associated with activity, in a model
that included mass as well. As before, we compared models with
and without the genetic variants and found that adding these six
SNPs decreased the polygenic variance by 9.4% and the residual
variance by 1.7%. For Lp-PLA2 mass, including rs1805017
decreases the polygenic variance by 12.2% and increases the
residual variance by 0.28%.
Relationship between top Lp-PLA2 activity loci and serum
lipid/lipoprotein levels
All four loci associated with Lp-PLA2 activity have generated
strong signals in previous association studies for lipid phenotypes
and include genes with established roles in lipid metabolism.
Therefore, interpreting the results requires understanding the
relationship between Lp-PLA2 activity and lipid/lipoprotein levels.
Figure 7 displays scatter plots (ignoring familial clustering) of Lp-
PLA2 activity with LDL-C (r=0.44), HDL-C (r=20.48), and
triglycerides (log-transformed, r=0.13). The linear trend and
moderate sample correlations with LDL-C and HDL-C imply that
markers associated with these lipoproteins may also be associated
with Lp-PLA2 activity to some extent. Indeed, both the APOE/
APOC1 locus and the CELSR2/PSRC1 locus have demonstrated
strong signals in genome-wide association studies of LDL-C [13].
Both loci were significantly associated with LDL-C in the present
study as well (Table 2), as previously reported [14]. In addition, the
APOE/APOC1 locus was weakly associated with HDL-C. We also
Figure 5. Genomic region surrounding the top hit near APOE/
APOC1. Location of rs4420638 is shown relative to genes in the region
of chromosome 19q13.
doi:10.1371/journal.pgen.1000928.g005
Table 2. Association (beta estimates and p values) of top activity and mass SNPs with Lp-PLA2 activity, mass, lipoproteins, and
apolipoproteins.
APOC1 PSRC1 SCARB1 ZNF259 PLA2G7
Top SNP rs4420638 rs599839 rs10846744 rs12286037 rs1805017
Distance to gene (bp) 340 10 0 0 0
Minor allele (frequency) G (0.16) G (0.22) C (0.15) T (0.07) T (0.26)
Regression coefficient (p value)
Lp-PLA2 activity 8.0 (5.9610
224) 25.5 (3.3610
215) 4.6 (1.2610
28) 6.4 (4.4610
28) 22.1 (1.5610
23)
Lp-PLA2 mass ns 24.6 (3.4610
23) 7.8 (1.4610
25) ns 11.1 (5.8610
214)
LDL-C 5.2 (3.3610
211) 25.7 (1.8610
216)n s n s n s
HDL-C 21.1 (3.3610
23)n s n s 22.2 (7.3610
25)n s
Triglycerides ns ns ns 1.1 (4.0610
211)n s
Apolipoprotein B 4.3 (5.6610
27) 24.7 (4.8610
210) ns 4.3 (4.6610
24)n s
Apolipoprotein A1 ns ns ns ns ns
Apolipoprotein E 22.1 (8.1610
231)n s n s n s n s
Apolipoproteins A and B were measured at Exam 4 and Apolipoprotein E measured at Exam 5 of the Offspring cohort. Therefore, the sample size (n=3144) differs from
the sample size used for SNP associations with Lp-PLA2 and lipoproteins, which were measured in both the Offspring cohort and the third generation cohort(n=6668).
All models controlled for age, age2, cohort, sex, lipid-lowering medication use, and smoking. P-values greater than 0.01 indicated as not significant (ns).
doi:10.1371/journal.pgen.1000928.t002
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PLoS Genetics | www.plosgenetics.org 5 April 2010 | Volume 6 | Issue 4 | e1000928Figure 6. PLA2G7 gene and surrounding region. Linkage disequilibrium (r
2) plot across the PLA2G7 gene region, including all SNPs significantly
associated with Lp-PLA2 mass (listed). Figure was generated from HapMap Caucasian data using Haploview software. Star indicates location of the
top SNP, rs1805017, in exon 4 of the PLA2G7 gene. Table to the right of the figure shows linkage disequilibrium (r
2) between all of the SNPs
associated with Lp-PLA2 mass and the top hit, rs1805017, generated from Framingham data.
doi:10.1371/journal.pgen.1000928.g006
Table 3. The effect of controlling for activity in analyses of Lp-PLA2 mass and vice versa on SNP associations, presented as
regression coefficient (p value).
SNP Closest Gene Activity Mass-adjusted Activity Mass Activity-adjusted Mass
rs4420638 APOC1 8.0 (5.9610
224) 7.9 (1.6610
228)n s 27.5(2.5610
26)
rs599839 PSRC1 25.5 (3.3610
215) 24.7 (1.4610
213) 24.6 (3.4610
23)n s
rs4970834 CELSR2 25.5 (6.8610
213) 24.7 (1.6610
211) 24.6 (6.7610
23)n s
rs10846744 SCARB1 4.6 (1.2610
28) 3.2 (1.1610
25) 7.8 (1.4610
25)n s
rs12286037 ZNF259 6.4 (4.4610
28) 5.5 (1.5610
27)n s n s
rs11820589 BUD13 6.2 (1.4610
27) 5.5 (3.1610
27)n s n s
rs1805017 PLA2G7 22.1 (1.5610
23) 24.2 (2.1610
212) 11.1 (5.8610
214) 13.3(4.3610
224)
rs12192544 SLC25A27 ns 23.0 (2.2610
26) 10.3 (4.7610
211) 11.4 (2.0610
216)
rs12528857 TDRD6 ns 23.0 (1.3610
26) 10.3 (5.0610
211) 11.5 (1.5610
216)
rs9369631 PLA2G7 ns 23.4 (1.7610
27) 10.3 (9.5610
211) 11.7 (1.3610
216)
rs1862008 PLA2G7 ns 23.4 (2.1610
27) 10.3 (1.1610
210) 11.7 (1.6610
216)
rs10948301 PLA2G7 ns 23.3 (2.4610
27) 10.2 (1.3610
210) 11.7 (2.0610
216)
rs9296510 PLA2G7 ns 23.4 (2.1610
27) 10.2 (1.3610
210) 11.7 (2.0610
216)
rs10807344 SLC25A27 ns 22.9 (3.4610
26) 10.0 (1.5610
210) 11.1 (1.0610
215)
rs9381477 PLA2G7 ns 23.4 (2.4610
27) 10.2 (1.6610
210) 11.6 (2.8610
216)
rs9296505 SLC25A27 ns ns 28.2 (3.7610
210) 28.0 (7.3610
212)
rs12211537 PLA2G7 ns ns 27.5 (9.2610
29) 27.4 (1.8610
210)
rs6901132 SLC25A27 21.9 (2.7610
23) 23.3 (4.6610
29) 7.5 (4.8610
28) 9.3 (2.5610
214)
rs1421378 PLA2G7 ns 22.6 (9.7610
27) ns 8.0 (1.0610
211)
rs6458511 CYP39A1 ns 22.3 (6.2610
25) ns 7.2 (8.4610
29)
*All models control for age, age2, cohort, sex, lipid-lowering medication use,and smoking. P-valuesgreater than 0.01 indicated as not significant (ns).
doi:10.1371/journal.pgen.1000928.t003
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triglyceride levels as reported in genome-wide association studies,
including the Framingham Heart Study [14]. SCARB1 polymor-
phisms have been associated with HDL-C, triglycerides, and LDL-
C in candidate-gene studies [15–22], but not in genome-wide
association studies. In the current study, however, the SCARB1
SNP was not associated with any of these lipids/lipoproteins.
Analysis of top SNP effects on Lp-PLA2 activity
controlling for lipids/lipoproteins
Because the top SNPs for Lp-PLA2 activity were in gene regions
known to associate with lipoprotein levels, we next asked whether
these SNPs remained significantly associated with Lp-PLA2 activity
beyond their reported association with serum lipids/lipoproteins.
For each SNP, we added LDL-C, HDL-C, or triglycerides as a
covariate to the original regression model. The association between
SNPs at the CELSR2/PSRC1 locus and Lp-PLA2 activity was
substantially reduced in a model accounting for their association
with LDL-C, but not eliminated (Table 4). In contrast, the APOE/
APOC1 locus remained strongly associated with Lp-PLA2 activity,
even after accounting for its association with LDL-C and HDL-C.
Similarly, when modeling the association between Lp-PLA2 activity
and the SNPs at the ZNF259/BUD13 locus, including triglycerides
or HDL-C as covariates did not appreciably reduce the association.
SCARB1 was not evaluated since the SNP showed no association
with lipoproteins in this study. Similarly, we did not further evaluate
Figure 7. Scatter plot of Lp-PLA2 activity against LDL cholesterol, HDL cholesterol, and triglycerides. Units are mg/dL for all lipids/
lipoproteins and nmol/ml/min for Lp-PLA2 activity. Triglycerides are log-transformed.
doi:10.1371/journal.pgen.1000928.g007
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associated with any lipoproteins.
Analysis of top activity SNPs associated with
apolipoprotein levels
Because our top loci all encompassed genes related to lipid
metabolism, and yet their association with lipid or lipoprotein
levels could not account for their association with Lp-PLA2
activity, we considered whether the effect of the SNPs was
mediated through some other factor. Some of our top hits are in
regions harboring apolipoprotein genes, so we examined the
association of our top loci with levels of apolipoproteins A1, B, and
E (measured only in the Offspring cohort). In addition, we expect
Lp-PLA2 activity to correlate with apolipoprotein B levels. The
CELSR2/PSRC1 and APOE/APOC1 SNPs were strongly associated
with apolipoprotein B levels, and the APOE/APOC1 SNP was also
very strongly associated with apolipoprotein E levels (Table 2).
None of our top SNPs were associated with apolipoprotein A1
levels. We were unable to further investigate the relationships
between associated SNPs, apolipoprotein levels, and Lp-PLA2
activity because the apolipoproteins were measured at different
exams than Lp-PLA2 activity.
Discussion
To gain insight into genetic variants that control Lp-PLA2
activity and mass, we conducted a genome-wide association study
using data from the Framingham Heart Study released through
the SHARe Project. We identified different loci associated with
each trait: four loci associated with Lp-PLA2 activity and one
associated with Lp-PLA2 mass. Variants in the region of PLA2G7,
encoding lipoprotein-associated phospholipase A2, were associated
with Lp-PLA2 mass, the strongest association being with a
common non-synonymous change, H92R. The four loci associ-
ated with Lp-PLA2 activity all harbor genes previously associated
with lipoprotein levels and known to be involved in lipid
metabolism. However, all of these loci remained significantly
associated with Lp-PLA2 activity after accounting for their
association with serum lipid and lipoprotein levels. Interestingly,
a fifth activity locus, PLA2G7, emerges as significant only after
controlling for mass.
Ours is not the first study to examine genetic variants associated
with Lp-PLA2 activity and mass; however, it is the first to do so on
a genome-wide level. A limited number of SNPs in PLA2G7,
encoding lipoprotein-associated phospholipase A2, have been
examined for association with Lp-PLA2 activity or mass. A
common non-synonymous change, rs1051931 (A379V), was
examined in several studies and found to be associated with
activity [11,23–25]. Abuzeid et al. [26] reported this same SNP
associated with mass. According to Hapmap data, this SNP is not
in linkage disequilibrium with our top SNP, rs1805017 (r
2=0.07).
A second common, non-synonymous European variant,
rs1805018 (I198T), was associated with activity in Chinese
population [27]. rs1805018 is not in linkage disequilibrium with
either rs1051931 or rs1805017 (r
2=0.02 for both). Neither the
A379V nor I198T locus was associated with Lp-PLA2 activity
(p=1610
24 and p=0.8, respectively) or mass (p=0.2 and
p=0.007) at a genome-wide level of significance in our study.
Our top SNP associated with mass was also a common non-
synonymous variant (H92R) in PLA2G7, and has not previously
been associated with Lp-PLA2 activity or mass, but has been
associated with coronary artery disease [28]. It is not clear whether
the H92R change is the causal variant at this locus, or a marker of
the causal variant. However, taken together with the other
literature, our results suggest that the non-synonymous variants at
this locus deserve further attention.
Our top locus for Lp-PLA2 activity, the APOE/APOC1 region,
has been previously reported by others. A candidate-gene study
conducted by Drenos and colleagues examined the APOE/APOC1
gene cluster for associations with multiple markers of cardiovascular
disease and found a strong association with Lp-PLA2 activity as well
as total cholesterol, LDL cholesterol, apolipoprotein B, and C-
reactive protein [29]. Thus, our study provides further evidence for
this candidate-region association and also implicates the APOE/
APOC1 gene cluster as the strongest locus associated with Lp-PLA2
activity on a genome-wide level. Interestingly, the rs4420638 SNP
associated with Lp-PLA2 activity in our study has also been
associated with LDL-C, Alzheimer’s disease, and C-reactive protein
in other genome-wide association studies [13,30–32]. Each copy of
the rs4420638 minor allele, G, was associated with increasing Lp-
PLA2 Activity. Based on patterns of linkage disequilibrium with the
APOE e2/e3/e4 genotypes, we would expect that carriers of the
APOE e4 allele would have increased Lp-PLA2 activity compared to
those with either the e2 or e3 alleles. In addition, we found a highly
significant association between the rs4420638 SNP and apolipo-
protein E levels. Whether these associations are causally related or
represent pleiotropic effects of this locus remains to be determined.
Early work on Lp-PLA2 suggested that it may be carried specifically
on apolipoprotein E-containing HDL, and this may bear further
investigation [33].
This is the first reported association between SNPs in the gene
regions of SCARB1, ZNF259/BUD13, and CELSR2/PSRC1 with
Lp-PLA2 activity. Although the identity of each causal genetic
variant and its target gene remains to be discovered, plausible
candidates can be found at each locus. SCARB1 encodes the
scavenger receptor class B type 1 (SR-BI), and is well-recognized
as an HDL receptor involved in reverse cholesterol transport.
Despite the well-established role of this gene in lipid metabolism,
to date genome-wide association studies, including those conduct-
ed with the Framingham Study, have not identified any genetic
variants of SCARB1 significantly associated with serum lipid levels
(http://genome.gov/gwastudies/). However, recent studies have
ascribed additional function to this receptor in regulating
inflammatory responses. In particular, in a mouse model of sepsis,
macrophages from SR-BI-null mice have been shown to produce
significantly higher levels of inflammatory cytokines than those of
wild type controls in response to LPS [34]. A recent study found
that SCARB1 rs10846744, associated with Lp-PLA2 activity in our
Table 4. Comparison of association of top activity SNPs in
statistical models with and without serum lipid/lipoprotein
levels, presented as regression coefficient (p value).
SNP Model 1 Lipid/lipoprotein Model 2
rs4420638 (APOC1)8 . 0 ( 6 610
224)L D L - C 5 . 6 ( 2 610
215)
rs4420638 (APOC1)8 . 0 ( 6 610
224)H D L - C 7 . 1 ( 2 610
222)
rs599839 (PSRC1) 25.5 (3610
215)L D L - C 22.6 (3610
25)
rs12286037 (ZNF259)6 . 4 ( 4 610
28)H D L - C 4 . 6 ( 2 610
25)
rs12286037 (ZNF259)6 . 4 ( 4 610
28) Triglycerides 5.4 (3610
26)
rs11820589 (BUD13)6 . 2 ( 1 610
27)H D L - C 4 . 6 ( 3 610
25)
rs11820589 (BUD13)6 . 2 ( 1 610
27) Triglycerides 5.3 (5610
26)
Model 1: controlled for age, age
2, sex, smoking, lipid-lowering medication, and
cohort. Model 2: included all Model 1 covariates and the indicated serum lipid/
lipoprotein.
doi:10.1371/journal.pgen.1000928.t004
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ethnic Study of Atherosclerosis [35]. The association was
independent of lipoprotein levels and other metabolic risk factors.
Given our findings, it is plausible that the association of SCARB1
SNPs with cardiovascular disease in their study could be mediated
through the inflammatory effects of SCARB1. The second locus
associated with Lp-PLA2 activity in our study is in the ZNF259/
BUD13 region, which includes the apolipoprotein genes APOA5,
APOA4, APOC3, and APOA1. This locus has been implicated in the
control of serum triglyceride levels and increased coronary artery
disease risk in a genome-wide association study [36]. APOA1
encodes apolipoprotein A1, which resides on HDL, interacts with
SR-BI, and has anti-inflammatory properties [37,38] The last
locus contains three genes, SORT1, PSRC1 and CELSR2, which
are relatively unexplored aside from their association with LDL
cholesterol in numerous genome-wide association studies
[13,14,36,39–42]. Recent studies suggest that the associated SNP
at this locus controls mRNA expression of the SORT1 gene
encoding sortilin 1 [13,43].
Lp-PLA2 is noncovalently bound to human plasma LDL and
HDL and the interaction with these lipoproteins largely deter-
mines its physiological activity [4,44]. The majority of Lp-PLA2 in
humans is bound to LDL, and subjects with elevated plasma LDL
cholesterol levels also have high Lp-PLA2 activity [5]. Thus, the
finding in our study that SNPs associated with serum lipoprotein
levels (specifically those associated with LDL cholesterol levels) are
also associated with Lp-PLA2 activity is not surprising. However,
the associations between these SNPs and Lp-PLA2 activity could
not be entirely accounted for by their associations with serum
lipid/lipoprotein levels. Moreover, it is interesting to note that
other known genetic determinants of LDL cholesterol levels, such
as SNPs at the APOB locus are not significantly associated with Lp-
PLA2 activity in our study. The ZNF259/BUD13 locus is more
strongly associated with triglycerides than LDL cholesterol in prior
genome-wide association studies and in the present study. This
result is consistent with the high Lp-PLA2 activity found associated
with small dense LDL, since hypertriglyceridemia shifts the
distribution of LDL toward smaller particle sizes [45]. Finally,
SCARB1 has not been associated with serum lipoprotein levels in
any genome-wide association study or in the present study.
Therefore, while lipid metabolism genes in general are rational
candidates due to the physical association of Lp-PLA2 with LDL
and HDL, the exact loci contributing to variation in Lp-PLA2
activity found in our study may provide further insight into the
relationship between Lp-PLA2 activity and lipoproteins.
Our study was carried out in the population-based Framingham
Heart Study, considered by some to be the gold standard for
cardiovascular-disease-related biomarker discovery and validation
[46]. Nonetheless, there are some caveats to note. First, quality-
control procedures for the genotype data removed a large number of
SNPs. It is possible that additional loci influencing Lp-PLA2 activity
and mass exist, but were not evaluated in our analysis. Second, it is
possible that the reported associations arise from confounding by
lipoprotein subspecies or inflammatory indices not measured in the
current study. We were able to explore this systematically for HDL-
C, LDL-C, and triglycerides. However, within the Offspring cohort,
Lp-PLA2 activity was measured at a different exam than
apolipoprotein levels, limiting our ability to properly assess potential
confounding by apolipoproteins. Finally, it would also have been
informative to examine not just total Lp-PLA2 measures, but Lp-
PLA2 by lipoprotein class and subclass, or indices of production by
specific cell types, but these data were not available.
In summary, we report the first genome-wide analysis for SNPs
associated with Lp-PLA2 activity and mass. For Lp-PLA2 activity,
SNPs in the APOE/APOC1 region, a region previously reported in a
candidate-gene study, emerged as the top hit on a genome-wide
scale. This same locus has been associated with apolipoprotein E
levels, LDL cholesterol levels, inflammatory traits, and cardiovas-
cular-disease outcomes. Future studies should be carried out to
determine if this locus is pleiotropic, or if it controls a mediator
related to both apolipoprotein E levels and Lp-PLA2 activity. Three
other loci associated with lipoprotein phenotypes were also highly
associated with Lp-PLA2 activity beyond their association with
serum lipid levels. Our study also confirmed the importance of
variants of the PLA2G7 gene in determining Lp-PLA2 mass. Lp-
PLA2 is an inflammatory marker that has been implicated in the
progression of atherosclerosis, and clinical trials of Lp-PLA2
inhibitors are currently in progress. Knowledge of genetic variation
that influences activity of Lp-PLA2 could have implications for
therapeutic intervention in this pathway.
Materials and Methods
Ethics statement
This research was approved by the Duke University institutional
review board and all clinical investigation was conducted
according to the principles expressed in the Declaration of
Helsinki.
Study population
We conducted this research using data from the Framingham
Heart Study (FHS), a population-based, longitudinal study of
families living in the town of Framingham, Massachusetts collected
over three-generations beginning in 1948. An overview of the FHS
is provided at the dbGap website (http://www.ncbi.nlm.nih.gov/
sites/entrez?db=gap) and detailed descriptions are available
elsewhere [47,48]. Briefly, the original study enrolled 5209
individuals, primarily Caucasian, and it later added the offspring
of the original cohort (Offspring), and the grandchildren
(Generation 3) of the original cohort.
All lipid-related traits were measured on fasting, plasma samples
stored at 280uC. Lp-PLA2 activity was measured during the
seventh exam of the Offspring cohort and first exam of the Third
Generation cohort using a colorimetric method (diaDexus CAM
Kit, Inc., San Francisco, CA). Apolipoprotein E concentrations
were measured during the fifth Offspring exam using an
immunochemical technique. Apolipoproteins A1 and B were
measured at the fourth exam by noncompetitive ELISA with the
use of affinity-purified polyclonal antibodies [49]. Triglycerides,
total cholesterol, and HDL-C were measured using standard
enzymatic methods, and LDL-C was calculated using the
Friedewald formula [50] if triglycerides levels were less than
400 mg/dL. Smokers were defined as individuals who indicated
that they smoked regularly within the past year of the exam.
Genotype data and quality control
Genome-wide genotypes and detailed clinical data on subjects
from all three generations have been made accessible to the
research community through the SHARe project (SNP-Health
Association Resource). The study protocol was approved by Duke
University’s Institutional Review Board and the Framingham
SHARe Data Access Committee. The unfiltered genotype data
contained 9215 individuals (all generations) genotyped for 549782
SNPs. This included 500568 SNPs from the Affymetrix 500K
mapping array and 49214 SNPs from the Affymetrix 50K
supplemental array (Affymetrix, Santa Clara, CA, USA). We used
the toolset PLINK to perform quality control [51]. Individuals
were excluded if genotyping rates were less than 97%. Markers
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frequencies were less than 0.05, or if Hardy-Weinberg p-values
were less than 0.001. All SNP exclusions were made sequentially in
the preceding order. Using this filtered data, we checked for
Mendel errors using a 5% cutoff per family, and a 10% cutoff per
SNP (as defined in PLINK), but none were detected. Individuals
were also excluded if the predicted sex based on X-chromosome
genotypes did not match the recorded sex. Pair wise identity-by-
descent measures were calculated to detect replicated samples and
unknown inter-familial relationships. We detected four sets of
identical twins and randomly selected one member of each pair for
the analytic sample. After quality controls, the remaining sample
consisted of 8493 individuals genotyped on 360811 SNPs,
attaining a genotyping rate of 99.5%. We also removed individuals
who had missing values for any covariates.
Statistical analysis
The primary analytic sample included 6668 individuals who
had both genotypes and Lp-PLA2 measurements available. We
tested SNPs for their association with Lp-PLA2 activity and mass
in an additive genetic model. To account for relatedness, we used
linear mixed models implemented in the kinship package of the R
statistical language. This allowed fitting an individual random
effect that was correlated according to the degree of relatedness
within a family [52]. Regression models included the covariates
age, age
2, sex, smoking status, a variable indicating the use of
cholesterol-lowering drugs, and a cohort variable corresponding to
the generation within the FHS. Subsequent analyses also included
serum lipoproteins in the regression model. We also tested for
evidence that population stratification was inflating test statistics.
To do this, we estimated the inflation factor by dividing the
median of the observed x
2 statistics by the expected median in the
absence of stratification (0.456) [53]. We defined genome-wide
significance using a Bonferroni cutoff of 1.461027, which corrects
for 360811 tests. Following genome-wide analysis, we annotated
results using the WGAViewer package, Ensembl, and the UCSC
genome browser [54–56]. We generated plots using the ggplot2
package [57] and Haploview software [58].
Supporting Information
Table S1 Analysis of SNPs associated with Lp-PLA2 activity.
Found at: doi:10.1371/journal.pgen.1000928.s001 (8.01 MB
TXT)
Table S2 Association of SNPs with Lp-PLA2 mass.
Found at: doi:10.1371/journal.pgen.1000928.s002 (8.37 MB
TXT)
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